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IN recent years synthetic analogues of cortisone and hydrocortisone have been
employed in the treatment of rheumatoid arthritis. Prednisone and prednisolone
were first used by Bunim, Pechet, and Bollet in 1955, and since then further reports
have followed (Dordick and Gluck, 1955; Margolis, Barr, Stolzer, Eisenbeis, and
Martz, 1955; Hart, Clark, and Golding, 1955; Boland, 1956; and Montgomery,
1957). Although the greater anti-rheumatic effects and lessened risks of sodium
retention in these compounds have been advantageous, most workers have been
concerned by the increased incidence of dyspepsia and gastro-(luodenal ulceration
which attended their use. Because of this and other disadvantages, the search for
newer compounds with fewer impleasant side-effects has continued, and recently
two new steroids, triamcinolone and 6 - methyl prednisolone have been discovered.
6 - Methyl prednisolone (Medrone Upjohn), which is the subject of this report, is
6 - methyl - A 1 - hydrocortisone and differs from prednisolone only in the sub-
stitution of a methyl group for an H atom in the 6 alpha position.
By means of animal experiments Lyster et al. (1957) have shown it to be three
times as potent as prednisolone using the glycogen deposition assay, and twice as
potent in anti-inflammatory activity by the granuloma pouch assay. No measurable
sodium or water retention was found;, and in fact, a sodium and water diuresis was
observed in the experimental animal. 6 - Methyl predisolone has also been shown
to be less susceptible to enzvmatic reduction bv the liver than prednisolone (Glen
et al., 1957).
In spite of these encouraging findings the earliest published report of the use of
6 - methyl prednisolone in rheumatoid arthritis was disappointing. Boland and
Liddle (1957) stated that it possessed no obvious advantage over prednisolone and
that both drugs exerted identical effects in equivalent doses. These findings are,
however, at variance with the results of Bilka and Melby (1958), who believed that
6 - methyl prednisolone was 25 per cent. more effective than prednisolone, while
Grater (1958) thought it was one and a half times more potent in the treatment of
allergic disorders.
Because of these conflicting opinions it was decided to carry out a clinical trial
of 6 - methyl prednisolone with the object of answering the following questions:
1. What is the potency of 6 - methyl prednisolone in comparison with pred-
nisolone?
2. Does 6
- methyl prednisolone possess any advantage over prednisolone in the
treatment of rheumatoid arthritis?
130NIETHO0).
Seven patienits xvith severe rheumiatoid arthritis xvere chlosen l'or study and
since the purpose of the trial was to compare 6 - methyl prednisolone with the
resuIlts achieved by prednisolone, only patients whlo hadl received prednisolone
previously and w\Nho were on a stable dose were selected. Before 6 - methyl
prednisolone Uwas adniinistered joint ftinctioni was assessed in accor(lancc with the
nmethod (lescribed prexiously (Montgoniery, 19.57). 'Ihereafter (i - methyl pred-
nisolone was substituted for prednisolonie, and was given, Ior the first two monithis
in almost equal doses. Owing, however, to the difference in the size of the two
tablets (6 - methyl prednisolone is manufactured as a 4 milligramme tablet) exact
matching doses could not be given easily and so xvere not attempted. TIwo months
later a small recluctioin in the dose of 6 - methyl prednisolotne wvas made and a
clinical assessment was carried out tlhen, and at 4 months, vhen the trial enldedl.
For details of dosage cemiployedl see 'I'able No. 1.
Becauise 6 - nmethlV prednisolone is ani oval shaped tablet, patients xvere aware that
a change lhad beenl miiade in their treatment. 'I'o avoidi undue emplhasis and comnient,
it was explained that the new tablets were almost identical with the old onies wlhile
no special ellthlLusiasnm was shown lor tlhemii.
1F~\BLE' I .
Dosage of predtiisolone (PI) and (i-methyl predniisolonie (6 MLIP) in milligrammllles.
CASE P - BEFORE START 6 - MP AT START Two MONTHS LATER 6 - MP AT END
No. OF TRIAL OFTRIAL 6 - MP REDUCED OF TRIAL
I10 ... 10 ... 8 ... 8
3 ... 12.5 ... 12I ... 10 ... 10
3 ... 12.5 ... 12 ... 10 ... 10
4 ... 2.5 ... 1 2 ... 122 ... I12
5 2.5 I I . 0 10
5 ... 12.5 ... 12 ... 10 ... 10
7 ... 12.5 ... 12 ... 10 ... 83
1. Case 2 inadvertently failed to take an extra half-tablet which was ordered.
2. Owing to this patient's general condition a reduction in dose was not possible.
3. One month before completion of the trial the dose was further reduced because of
her continued improvement.
RESUTLTS.
TIhe results obtaine(d at the various examinations are set out in tables 2, .3, 4, 5,
6 and 7. Althoughl no special questionls were directed towards the patients'
subjective symiiptoms, all expressed the opinion that the 'new' tablets were superior
to the old ones. WVhile thle trial was in pro-ress, cases 2 an(d 4 had complicating
illnesses wlhiclh made assessment difficult. Case 2 had had a chronic peptic ulcer,
resistanit to treatment for many montlhs, and when 6 - methyl prednisolone was
started svmptonms appeared to worsen. Since it was impossible to control the pain
anid as hlis arthritic con(lition neeessitatted the continuation of steroi(l therapy, a
partial g-astrectomv was successfully performied one mlonth -before the end of the
131trial. Case 4 developed an ischio-rectal abscess three months after the commence-
ment of 6 - methyl prednisolone treatment. This was drained and while he was
in hospital the opportunity was taken to repair an inguinal hernia. Both patients
were given additional amounts of Medrone to cover the stress imposed by their
surgical treatment, but as soon as possible the dose was reduced to the previous
level. In theory both should have improved with the enhanced dosage of 6 - methyl
prednisolone, but if the tables are perused it will be seen that their response was, in
fact, the poorest in the series. It is likely, therefore, that the complications altered
their physical condition and accounted, to some extent, for their indifferent progress.
TABLE 2.
Percentage increase (+) or decrease (-) in strengtlh of hand grip
over initial reading (both hands recorded together).
CASE ONE WEEK AFTER Two MONTHS AFTER Two MONTHS AFTER
No. STARTING 6-MP STARTING 6-MP REDUCTION IN 6-MP
1 ... + 28.3 ... +121.6 ... + 135.8
2 ... + 53.2 ... +117.7 ... + 2.1
3 ... + 28.9 ... + 64.1 ... + 75.9
4 ... + 3.4 ... - 14.2 ... - 32.8
5 ... + 15.8 ... + 33.6 ... + 38.6
6 ... + 73.4 ... +100.1 ... + 141.0
7 ... +181.0 ... +225.8 ... + 152.8
Strength of Grip.-An increase in strength was seen in all patients at the end
of one week's treatment, and in five the improvement was considerable. After two
months there were further gains in all but one (4) where the grip had weakened.
When the dose of 6 - methyl prednisolone was reduced, strength of grip remained
approximately the same in four patients but declined considerably in two (2 and
4) and to a lesser extent in one (7). Nevertheless, at the end of the trial, strength
exceeded the initial reading in five patients, very slightly in one (2) and was worse
only in one (4).
TABLE 3.
Measurement of finger swelling with Jewellers' Rings.
Percentage increase (+) and decrease (-) both hands.
CASE ONE WEEK AFTER Two MONTHS AFTER Two MONTHS AFTER
No. STARTING 6-MP STARTING 6-MP REDUCTION IN 6-MP
I ... - 2.3 ... - 4.6 ... - 8.9
2 ... no change ... - 3.7 ... - 5.2
3 ... - 4.1 ... -11.3 ... - 8.9
4 ... - 8.6 ... - 10.9 ... -16.7
5 ... -12.2 ... -.11.2 ... -13.8
6 ... - 3.1 ... - 8.7 ... -10.5
7 ... - 9.0 ... -13.5 ... -13.5
132Proximal interphalangeal joints.-During the four months' treatment with
6 - methyl prednioslone, interphalangeal joint size decreased slightly in all, and
none showed any increase over the initial reading. Even when the dose was reduced
the joints continued to regress in five (1, 2, 4, 5, 6).
Joint mobility.-An increase in joint movement was noted in five patients after
a week's treatment, but in twvo (1 and 5) it declined slightly. At two months,
movement had continue(d to improve, being malintaine(d on the reduced dose,
although there were slight individual variations.
TABLE 4.
Measurement of joint mobility to show percentage increase (+)
and decrease (-) in movement compared with initial reading
(movement of wrists, elbows, knees and ankles recorded).
CASE ONE WEEK AFTER Two MONTHS AFTER Two MONTHS AFTER
NO. STARTING 6 - MP STARTING 6- MP REDUCrION IN 6- MP
I - 0.6 ... + 5.2 ... +15.7
2 ... +18.6 ... +29.1 ... +26.1
3 ... +9.2 ... +12.4 ... +12.5
4 ... + 7.7 ... + 4.2 ... + 8.7
5 ... - 5.7 ... +10.0 ... + 4.2
6 ... +18.5 ... +24.9 ... +23.3
7 ... +20.8 ... +18.3 ... + 17.1
Knee-joint circzimference.-The changes in this measurement were minimal, but
the majority of cases showed a decrease in joint circumference during the period of
observation. 'I'he reduction in the dose of 6 - methyl prednisolone caused little
overall change.
TABLE 5.
Circumference of knee-joints to show
percentage increase (+) or decrease (-) in size
CASE ONE WEEK AFTER Two MONTHS AFIER Two MONTHS AFTER
No. STARTING 6- MP STARTING 6- MP REDUCrION IN 6- MP
1 -1.6 ... -0.3 ... -2.0
2 ... +0.9 ... +1.8 ... -0.4
3 . .. -1.1 . .. -5.7 . .. -8.4
4 ... -1.0 ... -1.7 ... +2.1
5 ... no change ... -3.1 ... -0.3
6 ... -2.3 ... -1.0 ... -2.6
7 ... -1.6 ... -1.2 ... -2.4
Erythrocyte Sedimentation Rate.,-The E.S.R. altered very little during the trial.
In three (5, 6, 7) it was reduced at the end of the study, in three (2, 3, 4) it was
increased and in one (1) it was unaltered.
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KT'ABLE 6.
Erythrocyte Sedimentation Rate.
WVIILE ON
PRFDNISOLONE
4
6
14
50
18
28
54
ONE WEEK
AFTFR STARTING
6-MP
4
75
20
3f6
15
12
41
Two MONTHS Two MONTHS
AFTEFR STARTING AFTFR REDUCTION
6-MP IN 6-MIP
8 ... 4
63 ... 76
16 ... 24
*5 ... 58
10 ... 12
13 ... 12
24 ... 26
TFeigldt.-Onlv one patient (1) gained weight. If cases 2 aindi 4 who had surgical
operations are excluded, the remaininig patients showed a slight loss of weight in
three (5, (, T) and a conisiderable loss in one (3). While these numbers are too
small from which to draw definite conclusions, it seems that patients on 6 - methyl
prednisolone are less pronie to gain wveight than those on prednisolone. It is of
interest that case 3, who lost 15 lbs. while on 6 - methyl prednisolone, had gained
weight excessively on prednisolone.
'ITABLE 7.
AWeight (lbs.)
WHILE ON
PRFDN I SOLONE
. 15')
. 150
. 146.5
. 144.5
. 180
176
122
ONE
WEEK
AFTER
STARTING
6- MP
148
151
145
144.5
178.5
175.5
119.5
Two
MONTHS
AFTER
STARTING
6 - MP
153
154
134.5
143
176
175.5
121
Two
MONTHS
AFTFER
RFDUCTION
IN 6-MP
153
144
131.5
134
179.5
174.5
120
OVFRALL
INCRFASF ( + )
OR DECREASE (-)
IN WEIGHT (LBS.)
DURING TREATMENT
WITH 6-MP
+ 3
- 6
... -15
... -10.5
... - 0.5
... - 1.5
... - 2
Side-effects of (6 - mtiethyl prednzisolonie treatmnent.-IBecause of their previous
long-term steroid treatment all patients had already experienced some unpleasant
side effects, and it was therefore difficult to know if 6 - methyl predcnisolone
lessened or increased these complications. Peptic ulceration is the most important
hazard of synthetic steroid treatment, and the reputation of any new compound
will be largely determined by the frequency of this complication. In this series one
patient who had a chronic peptic ulcer continued to have disabling symptoms, and
as already mentioned, a partial gastrectomy was carried out. It is unlikely that the
6 - methyl prednisolone made him much worse, for it seems virtually certain that
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CASE'
No.
3 2
4
5
6
7
CASF
No.
4
5
6
7the severity and(i chroinicity of the lesioln wXould have necessitatecl surgery, whiether
steroi(ls had been continuedl or not. One other patient (6) experienced mild
epigastric heaviness after meals which he had not had during, two and a half years'
treatment with prednisolone. This symptom developed three months after 6 - methyl
prednisolone was administered but cleared up quickly witlh a suitable dietary
regimle and antacids. A\ bariumll meal examination failed to show any ulcer or
abnormtality in the stomach or duodenuml.
Twno of tlle usual side-effects of prednisolone therapy seemled to b)e lessendl when
6 - methyl prednisoloiie was substitutel. The facial rounding or "Cushingoid"
facies so characteristically seenl in patients on long - term steroid treatment
diminished appreciably in three patients and considerably in a fourth (luring the
time they were taking, 6 - methyl prednisolone. Similarly f'acial flushing and the
accomnpanying burning sensation in the face w\as less proniounced in four patients,
pleasing several to w7homin it had been anl annoying feature of their previous
treatment.
'I'he tendency to bruiise which lhadl been observed in tlhrce patients was unchanged
whlen 6 - methyl prednisolone was beinig taken. No alteration in clectrolyte or water
metabolismii wx-as seen during the periodl of observation, an(l. no pat-ient had
glycosuria, hypertenision or mental dlisturbances as the result of changing to
6 - methyl prednisolone. One patient (4) developed a severe conmplicating infection
when on 6 - mthyl prednisolone and it is probable that the treatment effectively
masked the early symptoms allowing considerable spread of the infection before the
patient sought advice.
DiscUsSION.
Fromii thle evidenlce gained in this slhort trial it appears that 6 - miethyl prednisolone
was more effective than prednisolonie in relieving the synmptonms of rheumatoidl
arthritis. XWhen given in approximately equal doses joint performance and strengtlh
improved, and the patienit felt better. Reducing the dose of 6-methyl prednisolone
by between 17 and 20 per cent. still left the patient better off. 'I'he claim made by
the manufacturers that medrone is approximately 25 per cent. more potent than
prednisolone appears to be justified, and since the drug is marketed in a strength
of 4 milligrammes, this allows a tablet of Medrone to be substituted satisfactorily
for one of prednisolone.
Tahe results achieved demonstrate clearly that 6 - methyl prednisolone is an
effective suppressive agenit in the treatment of rheumatoid arthritis. WVhether it
possesses any inherent advantage over prednisolone cannot be assessed from thlis
short trial, but there are indications that some side-effects may be less pronounced.
Nevertheless, these are among the least serious, and the more important problem of
indigestion and peptic ulceration cannot yet be answered. It is obvious, however,
that it is impossible to compare the extent and frequency of side-effects of a new
steroid administered for a few months with older steroids given for protracted
periods. All that canI be done at present is to guess at trends, and an extended trial
is required before the severity and frequency of side-effects can be accurately
gauged.
135SUMMARY.
A clinical trial in whichl 6 - methyl prednisoloeti was compared with prednisolone
is described. Measurement of joint function was carriedl out at intervals to provide
objective evidence of therapeutic response. 'Fhe drug is an effective suppressive
agent for the treatment of rheumatoid arthritis and is slightly more powerful than
prednisiolone. Side effects appeared to be similar to those occurring with pre-
dnisolone but facial rounding and flushing, and increases in weight were less
pronounced. No opinion can be expressed about the effect of 6 - methyl prednisolone
on gastro-duodenal function.
It is concluded that 6 - methyl prednisolone is aI useful new steroid, and if
additional experience confirms that the increase in therapeutic efficiency is matched
by a reduced incidence of unpleasant side-effects, then it will probably become the
steroid of choice for the treatment of rheumatoid arthritis.
I wish to thank Dr. A. R. H. Hicks and Mr. R. G. Kenny of Upjohn of England Ltd.,
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co-operation. I am also indebted to Sister A. M. Wilson, S.R.N., for help with the clinical
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